WEED vs. OGI, GUD, ACB, CRON, TLRY, BHC, WELL, SIA, DNTL, and EXE
Should you be buying Canopy Growth stock or one of its competitors? The main competitors of Canopy Growth include Organigram (OGI), Knight Therapeutics (GUD), Aurora Cannabis (ACB), Cronos Group (CRON), Tilray Brands (TLRY), Bausch Health Companies (BHC), WELL Health Technologies (WELL), Sienna Senior Living (SIA), dentalcorp (DNTL), and Extendicare (EXE). These companies are all part of the "medical" sector.
Canopy Growth (TSE:WEED) and Organigram (TSE:OGI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, risk, media sentiment, dividends, institutional ownership, analyst recommendations, profitability and earnings.
4.3% of Canopy Growth shares are held by institutional investors. Comparatively, 9.0% of Organigram shares are held by institutional investors. 0.2% of Canopy Growth shares are held by insiders. Comparatively, 27.3% of Organigram shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Canopy Growth has a beta of 1.85, suggesting that its share price is 85% more volatile than the S&P 500. Comparatively, Organigram has a beta of 1.1, suggesting that its share price is 10% more volatile than the S&P 500.
Canopy Growth received 593 more outperform votes than Organigram when rated by MarketBeat users. Likewise, 62.44% of users gave Canopy Growth an outperform vote while only 44.76% of users gave Organigram an outperform vote.
Canopy Growth presently has a consensus target price of C$3.20, suggesting a potential downside of 76.23%. Organigram has a consensus target price of C$3.77, suggesting a potential upside of 44.32%. Given Organigram's stronger consensus rating and higher probable upside, analysts plainly believe Organigram is more favorable than Canopy Growth.
Canopy Growth has a net margin of 0.00% compared to Organigram's net margin of -153.80%. Organigram's return on equity of -54.53% beat Canopy Growth's return on equity.
In the previous week, Organigram had 5 more articles in the media than Canopy Growth. MarketBeat recorded 8 mentions for Organigram and 3 mentions for Canopy Growth. Canopy Growth's average media sentiment score of 0.72 beat Organigram's score of -0.50 indicating that Canopy Growth is being referred to more favorably in the media.
Organigram has lower revenue, but higher earnings than Canopy Growth. Organigram is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.
Summary
Organigram beats Canopy Growth on 10 of the 18 factors compared between the two stocks.
Get Canopy Growth News Delivered to You Automatically
Sign up to receive the latest news and ratings for WEED and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding WEED and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Canopy Growth Competitors List
Related Companies and Tools
